All In Biotech

Drug Trial Radar · NCT03281954

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Last checked: Nov 20, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,550 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,550

Actual

Start

Dec 19, 2017

Primary completion

Dec 31, 2024

Study completion Nov 30, 2027

Sponsor

Lead sponsor
NSABP Foundation IncResearch network
Sponsor type
Research network
Collaborators
Genentech, Inc.; Hoffmann-La Roche
First posted
Sep 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this study is paclitaxel (WP) and carboplatin followed by doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple negative breast cancer, no additional treatment is given unless the cancer returns. This study will also look at continuing treatment after surgery with atezolizumab or the placebo. To be better, atezolizumab given with the neoadjuvant therapy should be better at: 1) decreasing the amount of tumor in the breast than the placebo given with the usual chemotherapy and 2) decreasing the chance of the cancer from returning after surgery. Another purpose of this study is to test the good and bad effects of atezolizumab when added to the usual chemotherapy. Atezolizumab may keep your cancer from growing but it can also cause side effects.

Conditions

  • Triple Negative Breast Cancer

Interventions

  • PlaceboDrug

    Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses. Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles. \+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used. Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose.

  • AtezolizumabDrug

    Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses. Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles. \+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used. Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS)Time frame: From randomization until event, through study follow up to the time target number of events is obtained, up to 5 years

Locations

217 sites in 2 countries. Site status is shown where the registry gives one.

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Katmai Oncology Group

    Anchorage, Alaska

  • St. Bernard's Medical Center

    Jonesboro, Arkansas

  • St. Bernard's Medical Center

    Paragould, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Arrowhead Regional Medical Center

    Colton, California

  • City of Hope

    Duarte, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Kaiser Permanente-Harbor City

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • Kaiser Permanente-Sunset

    Los Angeles, California

  • Kaiser Permanente-West Los Angeles

    Los Angeles, California

  • Kaiser Permanente-Panorama City

    Panorama City, California

  • Kaiser Permanente-Riverside

    Riverside, California

  • Kaiser Permanente Medical Group

    San Diego, California

  • Kaiser Permanente-Zion

    San Diego, California

  • Kaiser Permanente - Otay

    San Diego, California

  • Kaiser Permanente- San Marcos

    San Marcos, California

  • City of Hope - South Pasadena

    South Pasadena, California

  • Torrance Memorial Physician Network

    Torrance, California

  • City of Hope - Upland

    Upland, California

  • PIH Health

    Whittier, California

  • Kaiser Permanente-Woodland Hills

    Woodland Hills, California

  • Mount Sinai Comprehensive Cancer Center Aventura

    Aventura, Florida

  • Memorial Healthcare System Office of Human Research

    Hollywood, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • UF Health Cancer Center at Orlando Health

    Orlando, Florida

  • Gwinnett Hospital System Center for Cancer Care

    Duluth, Georgia

  • Gwinnett Hospital System Center for Cancer Care

    Lawrenceville, Georgia

  • Gwinnett Hospital System Center for Cancer Care

    Snellville, Georgia

  • Illinois Cancer Care-Bloomington

    Bloomington, Illinois

  • John H. Stroger, Jr. Hospital of Cook County

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Affiliated Oncologists

    Chicago Ridge, Illinois

  • Cancer Care Specialists of Central Illinois

    Decatur, Illinois

  • Decatur Memorial Hospital

    Decatur, Illinois

  • Crossroads Cancer Center

    Effingham, Illinois

Showing 40 of 217 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.